This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
LQDA Stock Soars 129.7% YTD: Is There More Room for Growth?
by Ekta Bagri
Liquidia has surged 129.7% so far in 2026 as Yutrepia gains traction, driving strong sales, profitability and higher earnings estimates.
LQDANegative Net Change JNJNegative Net Change UTHRNegative Net Change
biotechnology biotechs medical pharmaceuticals
PTGX Stock Surges 64% in Six Months: What Is Driving the Rally?
by Zacks Equity Research
Protagonist shares rise as rusfertide nears an FDA decision and Icotyde adds milestone payments, royalties and broader pipeline momentum.
PTGXNegative Net Change JNJNegative Net Change ABBVNegative Net Change TAKNegative Net Change
biotechs
EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma
by Zacks Equity Research
AbbVie's EU approval expands Tepkinly into a first-of-its-kind bispecific lymphoma combination, backed by phase III data showing strong efficacy.
ABBVNegative Net Change AMRNNegative Net Change GMABPositive Net Change IMCRPositive Net Change
biotechs
AtaiBeckley Completes VLS-01 Dosing in Phase IIb Depression Study
by Zacks Equity Research
ATAI completes dosing in the phase IIb Elumina study of VLS-01 for treatment-resistant depression, with top-line efficacy and safety data due in fourth-quarter 2026.
ATAINegative Net Change NVAXNegative Net Change LQDANegative Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
VRTX to Strengthen Rare Disease Portfolio With $10B Crinetics Buyout
by Zacks Equity Research
Vertex to acquire CRNX for $10B, adding approved rare disease drug Palsonify and late-stage pipeline assets to expand its endocrinology portfolio.
VRTXNegative Net Change CRNXNegative Net Change NBIXPositive Net Change
biotechs medical pharmaceuticals
TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia
by Zacks Equity Research
TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.
TGTXNegative Net Change AMRNNegative Net Change LQDANegative Net Change IMCRPositive Net Change
biotechs
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition
by Zacks Equity Research
NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.
NVSNegative Net Change BAYRYPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Will the Label Expansion of Trodelvy Strengthen GILD's Oncology Portfolio?
by Ekta Bagri
Gilead wins FDA approval to expand Trodelvy into first-line mTNBC, boosting its market reach and strengthening its oncology growth strategy.
GILDNegative Net Change AZNNegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can Alnylam's Drug Pipeline Fuel Its Long-Term Revenue Growth?
by Ahan Chakraborty
ALNY's advancing pipeline and partnered programs can expand future revenue sources alongside its growing portfolio of approved therapies.
ALNYPositive Net Change REGNNegative Net Change PFENegative Net Change BBIOPositive Net Change
biotechnology biotechs medical pharmaceuticals
Reasons Why Investors Should Consider Betting on Neurocrine Stock
by Zacks Equity Research
NBIX builds on Ingrezza's momentum with pipeline advances and the Soleno acquisition, strengthening its long-term neuroscience growth strategy.
NBIXPositive Net Change AMRNNegative Net Change LQDANegative Net Change IMCRPositive Net Change
biotechs